

Å^{1/2}eljko Reiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4756874/publications.pdf>

Version: 2024-02-01

215
papers

65,704
citations

15001

68
h-index

1964

213
g-index

223
all docs

223
docs citations

223
times ranked

55547
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxidative stress mediated cytogenotoxicological effects of phytol in wistar albino rats. <i>Advances in Traditional Medicine</i> , 2023, 23, 273-290.	1.0	3
2	Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19. <i>International Journal for Vitamin and Nutrition Research</i> , 2022, 92, 49-66.	0.6	39
3	Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 328-339.	0.8	27
4	Prevalence of statin intolerance: a meta-analysis. <i>European Heart Journal</i> , 2022, 43, 3213-3223.	1.0	151
5	Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mediators of Inflammation</i> , 2022, 2022, 1-20.	1.4	42
6	Impact of Intravenous Trehalose Administration in Patients with Niemann-Pick Disease Types A and B. <i>Journal of Clinical Medicine</i> , 2022, 11, 247.	1.0	12
7	Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9 – A Narrative Review. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-6.	1.1	30
8	Differential Expression of miRNA-223 in Coronary In-Stent Restenosis. <i>Journal of Clinical Medicine</i> , 2022, 11, 849.	1.0	1
9	Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 820260.	1.1	27
10	Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 1313.	1.0	40
11	Step-by-step diagnosis and management of the nocebo/drugcebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622.	2.9	35
12	Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. <i>Atherosclerosis</i> , 2022, 348, 25-35.	0.4	18
13	Is there any association between plasma lipid profile and severity of COVID-19?. <i>Clinical Nutrition ESPEN</i> , 2022, , .	0.5	1
14	Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1018-1028.	0.6	3
15	New Therapeutic Approaches in Treatment of Dyslipidaemia – A Narrative Review. <i>Pharmaceuticals</i> , 2022, 15, 839.	1.7	15
16	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 370-379.	0.8	83
17	Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9?. <i>Critical Reviews in Food Science and Nutrition</i> , 2021, 61, 325-336.	5.4	7
18	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 33-43.	0.8	33

#	ARTICLE	IF	CITATIONS
19	Peripheral arterial disease and intermittent claudication in coronary heart disease patients. <i>International Journal of Cardiology</i> , 2021, 322, 227-232.	0.8	9
20	Statin therapy and sex hormones. <i>European Journal of Pharmacology</i> , 2021, 890, 173745.	1.7	10
21	Effects of statins on preeclampsia: A systematic review. <i>Pregnancy Hypertension</i> , 2021, 23, 123-130.	0.6	25
22	Novel Experimental Agents for the Treatment of Hypercholesterolemia. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 91-100.	1.5	14
23	Statin Therapy in Post-Operative Atrial Fibrillation: Focus on the Anti-Inflammatory Effects. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 24.	0.8	8
24	Resveratrol and cardiac fibrosis prevention and treatment. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, .	0.9	12
25	The role of statins in lung cancer. <i>Archives of Medical Science</i> , 2021, 18, 141-152.	0.4	11
26	Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2021, 166, 105499.	3.1	62
27	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.4	83
28	Pregnancy in Familial Chylomicronemia Syndrome: Plasmapheresis as Therapeutic Approach. <i>Journal of the Endocrine Society</i> , 2021, 5, A311-A311.	0.1	0
29	The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 682352.	1.1	5
30	In silico interactions of statins with cell death-inducing DNA fragmentation factor-like effector A (CIDEA). <i>Chemico-Biological Interactions</i> , 2021, 345, 109528.	1.7	4
31	Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection. <i>Frontiers in Pharmacology</i> , 2021, 12, 575877.	1.6	18
32	Fetal toxicity associated with statins: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2021, 327, 59-67.	0.4	30
33	Genistein as a regulator of signaling pathways and microRNAs in different types of cancers. <i>Cancer Cell International</i> , 2021, 21, 388.	1.8	30
34	Effects of Statins on Renin-Â“Angiotensin System. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 80.	0.8	7
35	Postmarketing nutriviigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. <i>Archives of Medical Science</i> , 2021, 17, 856-863.	0.4	19
36	Impact of Bariatric Surgery on Pulse Wave Velocity as a Measure of Arterial Stiffness: a Systematic Review and Meta-analysis. <i>Obesity Surgery</i> , 2021, 31, 4461-4469.	1.1	12

#	ARTICLE	IF	CITATIONS
37	Quercetin as a Novel Therapeutic Approach for Lymphoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-15.	1.9	19
38	The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mediators of Inflammation</i> , 2021, 2021, 1-12.	1.4	11
39	The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis. <i>Current Medicinal Chemistry</i> , 2021, 28, 6066-6081.	1.2	6
40	Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. <i>Journal of Clinical Medicine</i> , 2021, 10, 4930.	1.0	10
41	Prophylactic therapeutic plasma exchange in pregnant woman with Familial Chylomicronemia Syndrome – A case report. <i>Transfusion and Apheresis Science</i> , 2021, , 103346.	0.5	0
42	The Effect of Bariatric Surgery on Circulating Levels of Oxidized Low-Density Lipoproteins Is Apparently Independent of Changes in Body Mass Index: A Systematic Review and Meta-Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	1.9	12
43	Methotrexate for Cardiovascular Risk Reduction: The Right Choice?. <i>Angiology</i> , 2020, 71, 105-107.	0.8	11
44	The effects of catechin on endothelial function: A systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Food Science and Nutrition</i> , 2020, 60, 2369-2378.	5.4	10
45	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1630-1636.	0.8	23
46	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
47	Treatment of children with heterozygous familial hypercholesterolemia. <i>International Journal of Cardiology</i> , 2020, 304, 177-178.	0.8	5
48	Effects of resistant starch on glycemic control, serum lipoproteins and systemic inflammation in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled clinical trials. <i>Critical Reviews in Food Science and Nutrition</i> , 2020, 60, 3172-3184.	5.4	33
49	The effects of <i>n</i> -3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomised, double-blind, placebo-controlled trial. <i>British Journal of Nutrition</i> , 2020, 123, 792-799.	1.2	27
50	The effects of grape seed extract on glycemic control, serum lipoproteins, inflammation, and body weight: A systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , 2020, 34, 239-253.	2.8	34
51	The effects of saffron (<i>Crocus sativus</i> L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials. <i>Complementary Therapies in Medicine</i> , 2020, 48, 102250.	1.3	27
52	Medicinal plants and bioactive natural compounds as inhibitors of HMG-CoA reductase: A literature review. <i>BioFactors</i> , 2020, 46, 906-926.	2.6	30
53	The Therapeutic Potential of Anthocyanins: Current Approaches Based on Their Molecular Mechanism of Action. <i>Frontiers in Pharmacology</i> , 2020, 11, 1300.	1.6	152
54	Why might visit-to-visit variability of lipoproteins have an effect on cardiovascular events?. <i>Atherosclerosis</i> , 2020, 312, 99-100.	0.4	4

#	ARTICLE	IF	CITATIONS
55	Inflammatory Biomarkers for Cardiovascular Risk Stratification in Familial Hypercholesterolemia. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020, 177, 25-52.	0.9	13
56	A systematic review and meta-analysis: The effects of probiotic supplementation on metabolic profile in patients with neurological disorders. <i>Complementary Therapies in Medicine</i> , 2020, 53, 102507.	1.3	13
57	The effects of L-carnitine supplementation on indicators of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1879-1894.	0.8	29
58	Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer. <i>Cancer Cell International</i> , 2020, 20, 560.	1.8	39
59	Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. <i>Pharmacological Research</i> , 2020, 158, 104891.	3.1	62
60	Statins and the COVID-19 main protease: in silico evidence on direct interaction. <i>Archives of Medical Science</i> , 2020, 16, 490-496.	0.4	218
61	The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition ESPEN</i> , 2020, 38, 43-49.	0.5	21
62	The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. <i>Lipids in Health and Disease</i> , 2020, 19, 112.	1.2	31
63	The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair. <i>Heart Failure Reviews</i> , 2020, , 1.	1.7	1
64	The effects of omega-3 fatty acids supplementation on metabolic status in pregnant women: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1685-1699.	0.8	9
65	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020, 33, 155-179.	2.1	31
66	Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102381.	0.9	5
67	At a glance: economic impact of industry-sponsored clinical trials of pharmaceutical products. <i>Journal of Medical Economics</i> , 2020, 23, 1193-1195.	1.0	1
68	Molecular and Biological Functions of Quercetin as a Natural Solution for Cardiovascular Disease Prevention and Treatment. <i>Plant Foods for Human Nutrition</i> , 2020, 75, 307-315.	1.4	37
69	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	3.1	17
70	Effect of green cardamom on lipoproteins, glycemic control and anthropometric parameters: A meta-analysis of randomized clinical trials. <i>Clinical Nutrition ESPEN</i> , 2020, 37, 24-33.	0.5	6
71	The Effects of N-acetylcysteine on Inflammatory Markers and Homocysteine: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Pharmaceutical Sciences</i> , 2020, 26, 214-224.	0.1	0
72	The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. <i>Food and Function</i> , 2019, 10, 6042-6051.	2.1	121

#	ARTICLE	IF	CITATIONS
73	The effects of spirulina on glycemic control and serum lipoproteins in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , 2019, 33, 2609-2621.	2.8	25
74	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019, 140, 2054-2062.	1.6	83
75	Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units. <i>Journal of Clinical Medicine</i> , 2019, 8, 1742.	1.0	9
76	The Therapeutic Potential of Nanoparticles to Reduce Inflammation in Atherosclerosis. <i>Biomolecules</i> , 2019, 9, 416.	1.8	24
77	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019, 39, e1-e8.	1.2	31
78	The Role of Mesenchymal Stem Cells in Atherosclerosis: Prospects for Therapy via the Modulation of Inflammatory Milieu. <i>Journal of Clinical Medicine</i> , 2019, 8, 1413.	1.0	23
79	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM \pm) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	2.7	104
80	Can we further optimize statin therapy to increase tolerability?. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 843-847.	2.5	6
81	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019, 285, 135-146.	0.4	227
82	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019, 143, 1-16.	3.1	90
83	Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?. <i>Current Atherosclerosis Reports</i> , 2019, 21, 14.	2.0	15
84	A review of gene- and cell-based therapies for familial hypercholesterolemia. <i>Pharmacological Research</i> , 2019, 143, 119-132.	3.1	24
85	The association between lipid-lowering drugs and circulating concentration of PCSK9. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 928-929.	0.8	4
86	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 824-835.	0.8	558
87	Pulse wave velocity as a measure of arterial stiffness in patients with familial hypercholesterolemia: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , 2019, 15, 1365-1374.	0.4	18
88	Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry. <i>Journal of Hypertension</i> , 2019, 37, 2015-2023.	0.3	7
89	The year in cardiology 2018: prevention. <i>European Heart Journal</i> , 2019, 40, 336-344.	1.0	26
90	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. <i>European Journal of Epidemiology</i> , 2019, 34, 247-258.	2.5	22

#	ARTICLE	IF	CITATIONS
91	Macrophage: A Key Therapeutic Target in Atherosclerosis?. Current Pharmaceutical Design, 2019, 25, 3165-3174.	0.9	21
92	The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Pharmaceutical Design, 2019, 25, 3266-3281.	0.9	8
93	The effects of L-carnitine supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled trials. EXCLI Journal, 2019, 18, 631-643.	0.5	6
94	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Lipidology, 2018, 12, 801-809.	0.6	19
95	Improvement of endothelial function by pitavastatin: a meta-analysis. Expert Opinion on Pharmacotherapy, 2018, 19, 279-286.	0.9	26
96	PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis, 2018, 270, 187-188.	0.4	32
97	The importance of smoking cessation in patients with coronary heart disease. International Journal of Cardiology, 2018, 258, 26-27.	0.8	6
98	PCSK9 and infection: A potentially useful or dangerous association?. Journal of Cellular Physiology, 2018, 233, 2920-2927.	2.0	26
99	Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 2018, 8, e021508.	0.8	14
100	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. Korean Circulation Journal, 2018, 48, 1097.	0.7	15
101	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.4	163
102	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. Data in Brief, 2018, 21, 1334-1336.	0.5	4
103	The Role of Nutraceuticals in Statin-Intolerant Patients. Journal of the American College of Cardiology, 2018, 72, 96-118.	1.2	216
104	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. International Journal of Cardiology, 2018, 272, 20-25.	0.8	24
105	Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. Annals of Medicine, 2018, 50, 565-575.	1.5	36
106	Treatment of children with homozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2018, 25, 1095-1097.	0.8	13
107	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". Atherosclerosis, 2018, 275, 265-272.	0.4	131
108	Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Cardiovascular Drugs and Therapy, 2017, 31, 197-208.	1.3	22

#	ARTICLE	IF	CITATIONS
109	Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. <i>Complementary Therapies in Medicine</i> , 2017, 33, 1-5.	1.3	160
110	Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 53-65.	3.1	67
111	Hypertriglyceridaemia and risk of coronary artery disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 401-411.	6.1	257
112	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	2.6	238
113	Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1383-1401.	0.8	43
114	Statistical vs clinical significance: A matter of debate for orlistat treatment. <i>Pharmacological Research</i> , 2017, 124, 158-159.	3.1	0
115	Regular exercise behaviour and intention and symptoms of anxiety and depression in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 84-91.	0.8	20
116	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.4	206
117	Practical guidelines for diagnosing arterial hypertension of the Croatian Society of Hypertension of Croatian Medical Association and the Working Group on Hypertension of the Croatian Cardiac Society. <i>Cardiologia Croatica</i> , 2017, 12, 413-451.	0.0	2
118	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32.	1.2	90
119	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016, 18, C2-C12.	0.0	71
120	Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1618-1627.	0.8	19
121	Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1202-1210.	0.8	42
122	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>Atherosclerosis</i> , 2016, 253, 281-344.	0.4	1,189
123	Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1664-1678.	1.5	85
124	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	1.0	2,393
125	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 2007-2018.	0.8	153
126	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. <i>Thrombosis and Haemostasis</i> , 2016, 116, 162-171.	1.8	32

#	ARTICLE	IF	CITATIONS
127	Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. <i>Drugs</i> , 2016, 76, 947-956.	4.9	46
128	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 636-648.	0.8	772
129	Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey. <i>Atherosclerosis</i> , 2016, 246, 243-250.	0.4	173
130	Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016, 212, 160-168.	0.8	51
131	The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. <i>International Journal of Cardiology</i> , 2016, 209, 284-290.	0.8	77
132	Educational level and risk profile and risk control in patients with coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 881-890.	0.8	33
133	A Systematic Review and Meta-Analysis of Controlled Trials on the Effects of Statin and Fibrate Therapies on Plasma Homocysteine Levels. <i>Current Medicinal Chemistry</i> , 2016, 23, 4490-4503.	1.2	17
134	A comparison of European and US guidelines for familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2015, 26, 215-220.	1.2	13
135	Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. <i>Atherosclerosis</i> , 2015, 241, 169-175.	0.4	133
136	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015, 14, 133.	2.7	101
137	Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease?. <i>Cardiology</i> , 2015, 131, 225-227.	0.6	14
138	Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1212-1219.	0.8	33
139	Management of patients with familial hypercholesterolaemia. <i>Nature Reviews Cardiology</i> , 2015, 12, 565-575.	6.1	101
140	Cardiovascular disease (CVD) risk factors in older adults – Perception and reality. <i>Archives of Gerontology and Geriatrics</i> , 2015, 61, 88-92.	1.4	29
141	Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1354-1362.	0.8	81
142	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate – statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015, 19, 1-12.	1.2	66
143	PCSK9 inhibitors – past, present and future. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1517-1521.	1.5	37
144	Adverse Effects of Statins - Myths and Reality. <i>Current Pharmaceutical Design</i> , 2015, 21, 1220-1226.	0.9	107

#	ARTICLE	IF	CITATIONS
145	Similarities and differences between European and United States guidelines for the management of dyslipidaemias. <i>Kardiologia Polska</i> , 2015, 73, 471-477.	0.3	4
146	Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2014, 129, 999-1008.	1.6	197
147	Impact of Early Evidence of Atherosclerotic Changes on Early Treatment in Children With Familial Hypercholesterolemia. <i>Circulation Research</i> , 2014, 114, 233-235.	2.0	25
148	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014, 35, 960-968.	1.0	270
149	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 136.e1-136.e56.	0.6	15
150	Passive smoking and smoking cessation among patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. <i>European Heart Journal</i> , 2014, 35, 590-598.	1.0	44
151	Primary Prevention of Cardiovascular Disease with Statins in the Elderly. <i>Current Atherosclerosis Reports</i> , 2014, 16, 420.	2.0	28
152	Lysosomal acid lipase deficiency – An under-recognized cause of dyslipidaemia and liver dysfunction. <i>Atherosclerosis</i> , 2014, 235, 21-30.	0.4	232
153	Resistance and intolerance to statins. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 1057-1066.	1.1	183
154	Statins in the primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 453-464.	6.1	156
155	Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 799-807.	1.1	111
156	Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey. <i>Atherosclerosis</i> , 2013, 231, 300-307.	0.4	66
157	Polypill is not a “vaccine-like” solution for primary cardiovascular disease prevention in all parts of the world. <i>Journal of Epidemiology and Community Health</i> , 2013, 67, 981-982.	2.0	3
158	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
159	Mutation detection in Croatian patients with Familial Hypercholesterolemia. <i>Annals of Human Genetics</i> , 2013, 77, 22-30.	0.3	12
160	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	1.0	5,681
161	Prevalence and types of persistent dyslipidemia in patients treated with statins. <i>Croatian Medical Journal</i> , 2013, 54, 339-345.	0.2	30
162	Population-level changes to promote cardiovascular health. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 409-421.	0.8	106

#	ARTICLE	IF	CITATIONS
163	Guidelines, position papers and critical reviews: differences and similarities. European Journal of Preventive Cardiology, 2013, 20, 3-5.	0.8	9
164	Guidelines on CVD prevention: confusing or complementary?. European Journal of Preventive Cardiology, 2013, 20, 6-8.	0.8	2
165	Statins for primary prevention: problems with cardiovascular-risk estimation?. Nature Reviews Cardiology, 2013, 10, 547-547.	6.1	4
166	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	1.0	5,233
167	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	1.0	5,034
168	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis, 2012, 223, 1-68.	0.4	414
169	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1635-1701.	1.0	5,247
170	Guidelines on the management of valvular heart disease (version 2012). European Heart Journal, 2012, 33, 2451-2496.	1.0	3,465
171	Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. European Heart Journal, 2012, 33, 2865-2872.	1.0	59
172	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	2.9	2,307
173	Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques. Fundamental and Clinical Pharmacology, 2012, 26, 163-174.	1.0	32
174	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	1.2	2,558
175	Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality. Current Cardiology Reports, 2012, 14, 709-720.	1.3	93
176	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). International Journal of Behavioral Medicine, 2012, 19, 403-488.	0.8	224
177	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Revista Espanola De Cardiologia, 2012, 65, 938.e1-938.e59.	0.6	31
178	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	1.0	3,144
179	The perception and knowledge of cardiovascular risk factors among medical students. Croatian Medical Journal, 2012, 53, 278-284.	0.2	33
180	A pilot Croatian survey of risk factor (CRO-SURF) management in patients with cardiovascular disease. Collegium Antropologicum, 2012, 36, 369-73.	0.1	1

#	ARTICLE	IF	CITATIONS
181	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	1.0	993
182	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	1.0	2,767
183	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> . 2011, 32, 2851-2906.	1.0	1,394
184	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 1-44.	0.4	180
185	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 3-46.	0.4	561
186	Blood pressure control and knowledge of target blood pressure in coronary patients across Europe. <i>Journal of Hypertension</i> , 2011, 29, 1641-1648.	0.3	89
187	New ESC/EAS Guidelines for the management of dyslipidaemias âˆ“ any controversies behind the consensus?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 724-727.	3.1	13
188	Diabetic dyslipidemia or â€˜diabetes lipidusâ€™?. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 341-348.	0.6	18
189	Continental-Mediterranean and rural-urban differences in cardiovascular risk factors in Croatian population. <i>Croatian Medical Journal</i> , 2011, 52, 566-575.	0.2	23
190	Combined therapy in the treatment of dyslipidemia. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 19-28.	1.0	81
191	Management of overweight and obese patients with coronary heart disease across Europe. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 447-454.	3.1	36
192	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	1.0	1,392
193	EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 530-540.	3.1	193
194	Physiciansâ€™ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: The PERCRO-DOC survey. <i>Atherosclerosis</i> , 2010, 213, 598-603.	0.4	118
195	Public perceptions of cardiovascular risk factors in Croatia: The PERCRO survey. <i>Preventive Medicine</i> , 2010, 51, 494-496.	1.6	58
196	Combination therapy with prescription omega-3-acid ethyl esters and statin improves non-HDL-C more effectively than statin alone. <i>Clinical Lipidology</i> , 2010, 5, 325-328.	0.4	2
197	Unterschiede in den Risikofaktoren fÃ¼r koronare Herzkrankheit bei kroatischen Patienten von kontinentalen und mediterranen Regionen. <i>Wiener Klinische Wochenschrift</i> , 2008, 120, 684-692.	1.0	16
198	Title page. <i>American Journal of Cardiology</i> , 2008, 102, i.	0.7	103

#	ARTICLE	IF	CITATIONS
199	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. American Journal of Cardiology, 2008, 102, 1K-34K.	0.7	371
200	Statins in heart failure – A failure?. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 397-401.	1.1	1
201	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research, 2008, 5, 319-335.	0.9	227
202	Clinical Study on the Effect of Simvastatin on Paraoxonase Activity. Arzneimittelforschung, 2007, 57, 647-653.	0.5	11
203	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 13 BT /Over	0.784314	13
204	European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis, 2007, 194, 1-45.	0.4	292
205	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 13 BT /Over	0.784314	13
206	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 1.0 2,331 BT /Over	1.0	2,331
207	The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundamental and Clinical Pharmacology, 2007, 21, 1-3.	1.0	30
208	Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. Psychiatria Danubina, 2007, 19, 270-81.	0.2	15
209	Rice policosanol does not have any effects on blood coagulation factors in hypercholesterolemic patients. Collegium Antropologicum, 2007, 31, 1061-4.	0.1	4
210	Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 646-654.	3.1	35
211	Relation of Atherosclerotic Changes in Retinal Arteries to the Extent of Coronary Artery Disease. American Journal of Cardiology, 2005, 96, 1107-1109.	0.7	146
212	Clinical Study on the Effect of Simvastatin on Butyrylcholinesterase Activity. Arzneimittelforschung, 2005, 55, 271-275.	0.5	4
213	Effects of Rice Policosanol on Serum Lipoproteins, Homocysteine, Fibrinogen and C-Reactive Protein in Hypercholesterolaemic Patients. Clinical Drug Investigation, 2005, 25, 701-707.	1.1	42
214	Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service. Croatian Medical Journal, 2005, 46, 984-9.	0.2	13
215	Atherosclerosis of retinal arteries in men: role of serum lipoproteins and apoproteins. Croatian Medical Journal, 2004, 45, 333-7.	0.2	14